Top Abstract Purchase Related
Home
>
Node
>
Subnode

Pharmacological studies on the low molecular weight heparin derivative CY 216

Kaiser, B.; Kühnemuth, G.; Markwardt, F.

Die Pharmazie 45(7): 522-524

1990

ISSN/ISBN: 0031-7144
PMID: 2173004
Document Number: 347976
In animal experiments pharmacological properties of the low molecular weight heparin derivative CY 216 were determined. The heparin fragment studied caused concentration-dependent anticoagulant effects in vitro. Investigations in vivo demonstrated the antithrombotic potency of the drug in experimental models of venous and arterial thrombosis in rats. In dependence on the dose administered CY 216 reduced the formation of stasis-induced thrombi of the jugular vein and prevented the thrombotic occlusion of the carotid artery after electrically induced damage of the vessel wall. An influence on primary haemostasis measured by prolongation of bleeding time after standardized incision of the rat tail could only be observed at doses which were higher than that required for antithrombotic effects.

Document emailed within 1 workday
Secure & encrypted payments

Kaiser, B.; Hauptmann, J.; Markwardt, F. 1988: Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative Folia Haematologica 115(1-2): 119-125
Harenberg, J.; Stehle, G.; Dempfle, C.E.; von Hodenberg, E.; Heene, D.L. 1989: The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects Folia Haematologica 116(6): 967-980
Koppenhagen, K.; Tröster, E.; Matthes, M.; Häring, R. 1990: Prevention of thrombosis with low molecular weight heparin as the only substance and/or with DHE: results of clinical studies Langenbecks Archiv für Chirurgie. Supplement Ii Verhandlungen der Deutschen Gesellschaft für Chirurgie. Deutsche Gesellschaft für Chirurgie. Kongress 1990: 1163-1166
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Nakagawa, M. 1993: Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92
Bârzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J.P. 1984: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouvelle Revue Francaise d'Hematologie 26(4): 243-247
Morita, Y.; Makino, H.; Ota, K.; Wada, J.; Shikata, K.; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z. 1994: Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis Nihon Jinzo Gakkai Shi 36(7): 832-838
Chigot, P.; De Gennes, C.; Samama, M.M. 1996: Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin Journal des Maladies Vasculaires 21(3): 121-125
Hull, R.D.; Raskob, G.E.; Rosenbloom, D.; Pineo, G.F.; Lerner, R.G.; Gafni, A.; Trowbridge, A.A.; Elliott, C.G.; Green, D.; Feinglass, J. 1997: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective Archives of Internal Medicine 157(3): 289-294
Gouault-Heilmann, M.; Contant, G.; Pochmalicki, G.; Jan, F. 1984: Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin IIi Presse Medicale 13(22): 1393-1394
Mätzsch, T.; Bergqvist, D.; Blomquist, P.; Jiborn, H. 1987: Influence of standard heparin or low molecular weight heparin on healing of abdominal wounds and colonic anastomoses in rats Acta Chirurgica Scandinavica 153(10): 593-598
Mousa, S.A.; Fareed, J. 2001: Overview: from heparin to low molecular weight heparin: beyond anticoagulation Current Opinion in Investigational Drugs 2(8): 1077-1080
Wu, X.-x.; Chen, Y.; Tan, J.-p.; Liu, M.-l.; Zhang, J.-p. 2013: Modulation of low molecular weight heparin and heparin-binding epidermal growth factor on biological functions of human first trimester trophoblast Zhonghua Fu Chan Ke Za Zhi 48(2): 107-112
Osterkorn, D.; Schramm, W.; Szucs, T. 1996: Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home Medizinische Klinik 91(9): 607-609
Neri Serneri, G.G. 1993: Heparin, low-molecular-weight heparin and their clinical use Annali Italiani di Medicina Interna: Organo Ufficiale Della Societa Italiana di Medicina Interna 8(2): 69-72